Nelson Labs Expands Rapid Sterility Testing to U.S. and Europe

Nelson Labs, a global leader in microbiological and analytical chemistry testing, has expanded its Rapid Sterility Testing capabilities to three laboratory sites across the U.S. and Europe. Traditionally, sterility testing required a 14-day incubation period under USP <71>, but Nelson Labs’ innovative approach reduces this to as little as six days, depending on validation. This faster turnaround time allows medical device and pharmaceutical manufacturers to accelerate product release without compromising quality or safety.

“With Rapid Sterility Testing, we’re enhancing efficiency while maintaining the highest industry standards,” said Nina Moreno, Global Segment Director of Sterility Assurance at Nelson Labs. The company’s solution complies with USP <71> and <1223>, leveraging automated data analysis to minimize human error. Additionally, Nelson Labs’ regulatory experts are available to support manufacturers with validation and compliance, further streamlining the process of bringing safe, high-quality products to market.